Advertisement

Topics

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

20:01 EDT 3 May 2017 | Cancer Connect

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently […]

The post Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma appeared first on .

Original Article: Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma"

Quick Search
Advertisement
 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...